These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31208371)

  • 1. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
    BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    Sheng M; Sun R; Fu J; Lu G
    BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
    Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis.
    Wang X; Liu B; Xu M; Jiang Y; Zhou J; Yang J; Gu H; Ruan C; Wu J; Zhao Y
    Thromb Res; 2021 Apr; 200():72-80. PubMed ID: 33548843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
    Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
    Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
    J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer.
    Lee HY; Yu NY; Lee SH; Tsai HJ; Wu CC; Cheng JC; Chen DP; Wang YR; Tseng CP
    Biomed J; 2020 Apr; 43(2):146-162. PubMed ID: 32441651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
    Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N
    PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
    Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N
    Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin.
    Ogasawara S; Oki H; Kaneko MK; Hozumi Y; Liu X; Honma R; Fujii Y; Nakamura T; Goto K; Takagi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):318-26. PubMed ID: 26492619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.